Trial Profile

A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MC 0518 (Primary) ; Antithymocyte globulin; Etanercept; Infliximab; Methoxsalen; Ruxolitinib
Indications Graft-versus-host disease
Focus Therapeutic Use
Acronyms BALDER
Sponsors Medac

27 Jan 2026 Planned primary completion date changed from 1 Aug 2026 to 1 Mar 2026.
27 Jan 2026 Status changed from recruiting to active, no longer recruiting.
31 Jan 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com